Numinus Wellness NUMIF expanded its clinical research capabilities to Phoenix, where the psychedelics-assisted therapy provider currently operates mental health clinics.

This is Numinus’ third clinical trials research facility in the United States and fifth research site overall. It aims to provide management services to advance psychedelic science Cedar Clinical Research (CCR).

Founder and CEO Payton Nyquivest believes that this addition further cements Numinus as one of the leading research platforms for the sector.

See also: Sea Change – Irwin Naturals, Numinus and Field Trip discuss psychedelics in Cantor webinar

“Ultimately, this allows Numinus to support the growing body of research in the mental health and psychedelics field as we all work toward the goal of more indication-based evidence and safety data,” concluded Nyquvest.

The new location is in a leased facility adjacent to one of Numinus’ well-established wellness clinics. In fact, the first clinical study is scheduled to take place there from March 2023.

“Expanding to Phoenix allows us to scale our clinical research capabilities, allowing us to offer our current clients faster services and an expanded participant network while welcoming a growing list of biotech and psychedelics organizations,” CRO Paul Thielking called.

The site is “fully staffed” and could “come into operation as soon as possible,” he added.

Numinus also operates a Health Canada licensed laboratory that conducts proprietary research and development of psychedelics along with appropriate IP protection.

Photo: Benzinga edit with photo by Bacsica, aiyoshi597, Gisele Yashar, and August_0802 on Shutterstock.